Routine use of fluconazole prophylaxis in a neonatal intensive care unit does not select natively

Paolo Manzoni1, Marialisa Leonessa, Paolo Galletto

  • 1Neonatology and Hospital NICU, Azienda Ospedaliera Regina Margherita-S. Anna C. Spezia 60, 10136 Torino, Italy. paolomanzoni@hotmail.com

Insights

Routine fluconazole prophylaxis in very low birth weight (VLBW) infants did not increase rates of fluconazole-resistant Candida species. This antifungal strategy remains effective for preventing fungal colonization and infection in this vulnerable population.

Area of Science:

  • Neonatal Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • Fluconazole prophylaxis is standard for very low birth weight (VLBW) infants to prevent fungal infections.
  • Prolonged use raises concerns about emerging antifungal resistance and fluconazole-resistant Candida species.

Purpose of the Study:

  • To assess the impact of routine fluconazole prophylaxis on the incidence of fluconazole-resistant Candida species in VLBW infants.
  • To compare the prevalence of resistant Candida species before and after the implementation of prophylaxis.

Main Methods:

  • Retrospective analysis of clinical and surveillance fungal isolates from VLBW infants over a 10-year period (1997-2006).
  • Fungal isolates were speciated, and incidence rates of colonization and infection by natively fluconazole-resistant (NFR) Candida species were calculated.
  • Comparison between a 6-year prophylaxis period (2001-2006) and a 4-year preprophylaxis period (1997-2000).

Main Results:

  • Colonization by NFR-Candida species ranged from 2.8% to 6.6% annually, with no increasing trend observed.
  • 18 of 434 (4.1%) VLBW infants were colonized by NFR-Candida species.
  • Five systemic infections (1.1% incidence) by NFR-Candida species occurred, with no significant difference compared to the preprophylaxis period (3.7% colonization, 1.4% infection).

Conclusions:

  • Routine fluconazole prophylaxis in VLBW neonates does not lead to the emergence of natively fluconazole-resistant Candida species.
  • The antifungal prophylaxis strategy remains effective in preventing resistant fungal infections in this population.
Abstract

Related Concept Videos

Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...